Search Results 1541-1550 of 21896 for Inhibition
... inhibitor within 14 days impacted in the presence of a CYP3A4 inhibitor within 14 days of screening. Patient has not remained at stables doses of all drugs ...
Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in Pulmonary Hypertension in Interstitial Lung Disease: A PVRI GoDeep Meta- ...
- Known significant bleeding sources other than nasal or gastrointestinal. - Systemic use of a potent VEGF inhibitor (e.g., direct inhibitors of VEGF-receptor
A regimen that included an immunomodulatory agent (e.g., thalidomide, lenalidomide, pomalidomide) and a proteasome inhibitor (e.g., bortezomib, carfilzomib ...
... inhibitors (ACEIs) or angiotensin II type I receptor blockers (ARBs). Participation eligibility. Participant eligibility includes age, gender, type and stage ...
... inhibitors (such as indinavir), amiodarone, gemfibrozil, cyclosporine, verapamil, danazol, nefazodone, and red yeast rice extracts; Active liver disease ...
... inhibitors, heparin, factor Xa inhibitors, low molecular weight heparin) * High dose antiplatelet therapy (\>325mg acetylsalicylic acid or \>75mg ...
... inhibitors (these patients being allowed to have more advanced disease). ... Planned receipt of chemotherapy or another cancer-directed therapy concurrently (e.g. ...
It belongs to a group of medicines known as selective serotonin and norepinephrine reuptake inhibitors (SSNRIs). These medicines work by increasing the ...
... inhibitors. However, few of these patients had HF, and those that did were not well-characterized. Thus, the effects of sodium-glucose co-transporter-2 ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!